Adam Nadelson

Pasithea Therapeutics Corp. (NASDAQ: KTTA), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, announced on Wednesday that its wholly-owned subsidiary, Pasithea Clinics, commenced clinical operations,...